Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.
Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.
It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back of the biotech firm’s successful Phase 2a PIONEER …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are shooting up almost 17% with investors clearly paying keen attention to the biotech firm’s Parkinson’s Disease Psychosis …
Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …
What does GlycoMimetics Inc’s (NASDAQ:GLYC) abstract data for the American Society for Clinical Oncology (ASCO) bring to the table for acute myeloid leukemia …
Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), as it appears that payors are still actively …